These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38167464)

  • 1. Implementation status of pharmacological studies in the development of orphan drugs.
    Yokoshiki S; Arato T
    Orphanet J Rare Dis; 2024 Jan; 19(1):5. PubMed ID: 38167464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
    Vokinger KN; Kesselheim AS
    BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
    Nakayama H; Matsumaru N; Tsukamoto K
    Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
    Kesselheim AS; Myers JA; Avorn J
    JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
    Michaeli T; Jürges H; Michaeli DT
    BMJ; 2023 May; 381():e073242. PubMed ID: 37160306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
    Stockklausner C; Lampert A; Hoffmann GF; Ries M
    Oncologist; 2016 Apr; 21(4):487-93. PubMed ID: 27022038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unique characteristics of regulatory approval and pivotal studies of orphan anticancer drugs in Japan.
    Nakayama H; Tsukamoto K
    Invest New Drugs; 2018 Aug; 36(4):702-708. PubMed ID: 29667133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
    Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Profile of Novel Anti-cancer Drugs Approved by USFDA in 2022: A Review.
    Sangwan K; Sharma V; Goyal PK
    Curr Mol Med; 2024; 24(6):734-750. PubMed ID: 37350009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
    Maier WC; Christensen RA; Anderson P
    Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes in Orphan Drug Labels Approved by the US Food and Drug Administration.
    Hong YD; Villalonga-Olives E; Perfetto EM
    Value Health; 2019 Aug; 22(8):925-930. PubMed ID: 31426934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of orphan products by the U.S. Food and Drug Administration.
    Haffner ME; Kelsey JV
    Int J Technol Assess Health Care; 1992; 8(4):647-57. PubMed ID: 1464485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments.
    Winstone J; Chadda S; Ralston S; Sajosi P
    Orphanet J Rare Dis; 2015 Oct; 10():139. PubMed ID: 26511061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending.
    Michaeli T; Michaeli DT
    Value Health; 2024 Apr; 27(4):449-457. PubMed ID: 38244983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
    Yamashita K; Kaneko M; Narukawa M
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The drug development pipeline for glioblastoma-A cross sectional assessment of the FDA Orphan Drug Product designation database.
    Johann P; Lenz D; Ries M
    PLoS One; 2021; 16(7):e0252924. PubMed ID: 34234357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.